ISRS delivers its 100th Webinar
Since we launched our webinar program in Oct 2016 we have delivered webinars on a fortnightly basis covering important topics related to intracranial and body SRS. These have become increasingly popular during the pandemic attracting hundreds of registrants. We have now completed our 100th webinar. This has all been made possible due to the generosity of the speakers who have given up their time to give high level lectures. Members can access recording of all of the webinars via our website: Access the library here.
Post-operative Spine Stereotactic Body Radiation Therapy
Director of Spinal Oncology Multi-Disciplinary Program
Department of Radiation Oncology and Molecular Radiation Sciences
The Johns Hopkins University
Baltimore, MD, USA
May 21, 2021, 1:00PM BST
Post-operative spine SBRT is being increasingly performed at both community and academic practices. However, there are specific nuances for post-operative cases that are unique and a firm understanding of the surgery performed is essential. This webinar will include a brief introduction to spine SBRT. We will then review of current surgical trends and techniques, including epidural disease grading and assessment of spinal instability using the SINS scoring system; the pros and cons of surgery in patients with metastatic disease and why prophylactic surgery may be undertaken for instability; an overview of en bloc surgery and minimally invasive surgery. Next we will review current data on conventional post-operative radiation therapy versus post-operative spine SBRT with a focus on local control and pain control including a discussion of the degree of epidural resection that is optimal. We will present a detailed description of the post-operative spine SBRT radiation technique, including delineation of the optimal target volume; organ at risk delineation including precise delineation of the cord when there is hardware creating artifact on MRI; accounting for hardware in treatment planning; toxicities unique to post-operative patients such as hardware failure or fracture; and reasonable dose constraints for radiation naïve and previously irradiated patients. We will end by discussing future directions and research questions including trends towards more limited surgery and use of post-operative SBRT to consolidate.
Molecular Profiling in Gliomas: Current Applications and Future Directions
Neurologist, Sunnybrook Health Sciences Centre
Clinician Investigator, Faculty of Medicine, University of Toronto, Canada
June 04, 2021, 1:00PM BST
Advances in next generation sequencing has brought molecular profiling to the forefront of clinical care in glioma patients. This presentation will review the emerging clinical applications of molecular profiling of gliomas and review their predictive and prognostic utility. It will also specifically discuss the importance of molecular profiling in young adult glioma patients and discuss emerging targeted therapy options.
Breaking Barriers with Sound: Current and Emerging Indications for MR-guided Focused Ultrasound
June 18, 2021, 1:00PM BST
Focused ultrasound (FUS) is a disruptive medical technology, and its implementation in the clinic represents the culmination of decades of research. With the ability to non-invasively and precisely intervene in key structures, FUS offers a new means of interacting with dysfunctional brain circuits. The last decade has seen a dramatic expansion of indications for and experience with FUS in humans, with applications now spanning the clinical spectrum from neurological to psychiatric and oncologic diseases. This talk will examine the impact of FUS on the landscape of brain therapies as well as the challenges facing the advancement and broader adoption of this promising minimally invasive therapeutic alternative.
Medical Management of Breast Cancer Brain Metastases
June 28, 2021, 1:00PM BST
Patients with metastatic breast cancer, particularly those with triple negative or HER2+ disease, are at high risk of developing brain metastases. The risk of brain metastases and time to development of brain metastases by breast cancer subtype will be discussed. In addition, the intra-cranial efficacy of systemic therapy for patients with breast cancer brain metastases will be reviewed, with a focus on HER2-targeted therapies. Approaches to investigating novel systemic therapies for patients with brain metastases will also be discussed.